Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Centrais Eltricas Brasileiras S.A. - Eletrobras, through its subsidiaries, engages in the generation, transmission, and distribution of electricity in Brazil. The company generates electricity through hydroelectric, thermal, nuclear, wind, and solar plants. As of December 31, 2021, it owned and operated 32 hydroelectric plants with a total installed capacity of 46,295.75 megawatts; nine thermal plants, including coal, and oil and gas power generation units with a total installed capacity of 1,505 megawatts; and two nuclear power plants comprising Angra I with an installed capacity of 640 megawatts and Angra II with an installed capacity of 1,350 megawatts. It also operates 66,556 kilometers of transmission lines. The company was incorporated in 1962 and is based in Rio de Janeiro, Brazil.

Centrais Eltricas Brasileiras S.A. - Eletrobrs

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

JACKSONVILLE, FLA.--(BUSINESS WIRE)--INCISIV, A NEXT-GENERATION INDUSTRY INSIGHTS FIRM THAT HELPS RETAILERS AND BRANDS NAVIGATE DIGITAL DISRUPTION, HAS ANNOUNCED THE RELEASE OF ITS 2023 OMNICHANNEL RETURNS INDEX IN PARTNERSHIP WITH APPRISS RETAIL, AN INDUSTRY LEADER OF DATA-SCIENCE-DRIVEN SOLUTIONS THAT CAN HELP OPTIMIZE CONSUMER INTERACTIONS AND REDUCE FRAUD RISK. THIS SECOND EDITION OF THE BENCHMARK ASSESSES 128 LEADING RETAILERS ACROSS NINE RETAIL SUB-SEGMENTS, FOUR CAPABILITY AREAS, AND 80 DIGITAL EXPERIENCE CAPABILITIES RELATED TO RETURNS. AS THE SHARE OF DIGITAL REVENUE HAS GROWN, THE BENCHMARK STUDY FOUND THAT SHOPPERS RETURN ONLINE PURCHASES THREE TO FOUR TIMES MORE THAN STORE-BOUGHT PURCHASES. DESPITE THIS TREND, MOST RETAILERS HAVE YET TO TAKE A STRATEGIC APPROACH TO REDUCING RETURNS AND CONTINUE TO VIEW THEM AS A COST OF DOING BUSINESS. IN FACT, ONLY 19% OF RETAILERS HAVE A STRATEGIC RETURNS PROGRAM IN PLACE. THE STUDY DEMONSTRATES THAT MOST RETAILERS HAVE A LIMITED UNDERSTANDING OF THEIR RETURNS PERFORMANCE AND ARE ILL-EQUIPPED TO IMPROVE THE PROCESS, PRIMARILY DUE TO A LACK OF CLEARLY DEFINED METRICS AND MEASURES. THE TWO RETAIL SEGMENTS THAT HAVE THE HIGHEST ADOPTION OF DIGITAL RETURNS CAPABILITIES ARE HEALTH AND BEAUTY, AND APPAREL AND ACCESSORIES. MEANWHILE, DEPARTMENT STORES AND CONSUMER ELECTRONICS RETAILERS LEAD THE INDUSTRY IN RETURN PROCESSES AND CUSTOMER SUPPORT CAPABILITIES. ADDITIONAL KEY FINDINGS FROM THE INDEX INCLUDE: 91% OF APPAREL AND ACCESSORIES RETAILERS ALLOW RETURNS TO BE INITIATED ONLINE. 87% OF DEPARTMENT STORE RETAILERS ALLOW RETURNS TO BE INITIATED VIA CHAT. 79% OF HEALTH AND BEAUTY RETAILERS PROVIDE PERSONALIZED PRODUCT RECOMMENDATIONS. 78% OF CONSUMER ELECTRONICS RETAILERS ALLOW SHOPPERS TO PRINT RETURN LABELS ONLINE. DESPITE THESE STRATEGIC ATTEMPTS TO STRENGTHEN THE ONLINE RETURNS PROCESS, MOST RETAILERS HAVE SIGNIFICANT ROOM FOR IMPROVEMENT WHEN IT COMES TO MEETING SHOPPER EXPECTATIONS. THE REPORT FOUND THAT: 76% OF RETAILER

INCISIV RELEASES 2023 OMNICHANNEL RETURNS INDEX WITH BEST PRACTICES FOR STRONGER RETURNS MANAGEMENT

IRVINE, CALIF.--(BUSINESS WIRE)--APPRISS RETAIL, AN INDUSTRY LEADER IN THE DATA SCIENCE TRANSFORMING CONSUMER INTERACTIONS AND LOSS PREVENTION, TODAY ANNOUNCED THAT IT HAS BEEN NAMED A LEADER IN THE RIS SOFTWARE LEADERBOARD 2023. APPRISS RETAIL RANKED IN THE OVERALL TOP 20, AS WELL AS IN THE TOP 10 FOR 24 INDIVIDUAL CATEGORIES, WITH STANDOUT MENTIONS IN THE AREAS OF CUSTOMER SERVICE AND SUPPORT. THE RIS SOFTWARE LEADERBOARD IS ONE OF THE RETAIL INDUSTRYS MOST PRESTIGIOUS BENCHMARK REPORTS. AFTER SURVEYING THE CUSTOMER BASE FOR MANY WELL-KNOWN RETAIL TECHNOLOGY COMPANIES, RIS NEWS RANKS THESE VENDORS BASED ON CUSTOMER SATISFACTION, PERFORMANCE, AND VALUE. THE REPORT HIGHLIGHTS ONE OVERALL TOP 20 AND VARIOUS TOP 10 LISTS FOR SPECIFIC CRITERION. APPRISS RETAIL RANKED IN THE TOP 20 AND RECEIVED TOP FIVE RANKINGS FOR NUMEROUS ADDITIONAL CATEGORIES, INCLUDING BUT NOT LIMITED TO: LEADERS IN QUALITY OF SERVICE (#1) LEADERS IN QUALITY OF SUPPORT BY TIER ONE & MID-SIZE RETAILERS (#1) LEADERS IN TOTAL COST OF OPERATIONS BY TIER ONE & MID-SIZE RETAILERS (#2) LEADERS IN OVERALL PERFORMANCE BY TIER ONE AND MID-SIZE RETAILERS (#3) LEADERS IN TECHNOLOGY INNOVATION (#3) LEADERS IN EASE OF INSTALLATION AND INTEGRATION (#4) LEADERS IN SOFTWARE RELIABILITY BY TIER ONE & MID-SIZE RETAILERS (#4) THE RELATIONSHIP BETWEEN APPRISS RETAIL AND ITS CUSTOMERS IS OF THE UTMOST IMPORTANCE TO OUR TEAM, SO SEEING THAT REFLECTED IN THE RANKINGS MEANS A LOT, SAID STEVE PREBBLE, CEO, APPRISS RETAIL. OUR TECHNOLOGY IS DESIGNED TO HELP RETAILERS MAXIMIZE THEIR PROFITS WHILE MANAGING THEIR RISK THROUGH REAL-TIME DECISION MAKING AND ACTIVE RISK ASSESSMENTS. THIS IS A SENSITIVE, YET IMPORTANT, AREA FOR RETAILERS, AND WE ARE DEDICATED TO ENSURING OUR CUSTOMERS RECEIVE GREAT ROI AND STRONG REVENUE BOOSTS. SEEING THESE EFFORTS, AND OUR ONGOING, INNOVATIVE APPROACH TO SOLVING MARKET CHALLENGES, REFLECTED IN THE RIS SOFTWARE LEADERBOARD AGAIN THIS YEAR IS AN HONOR. THIS IS THE SECOND YEAR IN A ROW THAT WEVE SEE

APPRISS RETAIL SHINES IN THE CUSTOMER SERVICE AND SUPPORT CATEGORIES IN THE RIS SOFTWARE LEADERBOARD 2023

DUBLIN--(BUSINESS WIRE)--THE "CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET RESEARCH REPORT BY PRODUCT, END-USER, REGION - GLOBAL FORECAST TO 2027 - CUMULATIVE IMPACT OF COVID-19" REPORT HAS BEEN ADDED TO RESEARCHANDMARKETS.COM'S OFFERING. THE GLOBAL CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE WAS ESTIMATED AT USD 4,314.82 MILLION IN 2021, USD 4,635.07 MILLION IN 2022, AND IS PROJECTED TO GROW AT A CAGR 7.59% TO REACH USD 6,696.03 MILLION BY 2027. COMPETITIVE STRATEGIC WINDOW: THE COMPETITIVE STRATEGIC WINDOW ANALYSES THE COMPETITIVE LANDSCAPE IN TERMS OF MARKETS, APPLICATIONS, AND GEOGRAPHIES TO HELP THE VENDOR DEFINE AN ALIGNMENT OR FIT BETWEEN THEIR CAPABILITIES AND OPPORTUNITIES FOR FUTURE GROWTH PROSPECTS. IT DESCRIBES THE OPTIMAL OR FAVORABLE FIT FOR THE VENDORS TO ADOPT SUCCESSIVE MERGER AND ACQUISITION STRATEGIES, GEOGRAPHY EXPANSION, RESEARCH & DEVELOPMENT, AND NEW PRODUCT INTRODUCTION STRATEGIES TO EXECUTE FURTHER BUSINESS EXPANSION AND GROWTH DURING A FORECAST PERIOD. FPNV POSITIONING MATRIX: THE FPNV POSITIONING MATRIX EVALUATES AND CATEGORIZES THE VENDORS IN THE CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET BASED ON BUSINESS STRATEGY (BUSINESS GROWTH, INDUSTRY COVERAGE, FINANCIAL VIABILITY, AND CHANNEL SUPPORT) AND PRODUCT SATISFACTION (VALUE FOR MONEY, EASE OF USE, PRODUCT FEATURES, AND CUSTOMER SUPPORT) THAT AIDS BUSINESSES IN BETTER DECISION MAKING AND UNDERSTANDING THE COMPETITIVE LANDSCAPE. MARKET SHARE ANALYSIS: THE MARKET SHARE ANALYSIS OFFERS THE ANALYSIS OF VENDORS CONSIDERING THEIR CONTRIBUTION TO THE OVERALL MARKET. IT PROVIDES THE IDEA OF ITS REVENUE GENERATION INTO THE OVERALL MARKET COMPARED TO OTHER VENDORS IN THE SPACE. IT PROVIDES INSIGHTS INTO HOW VENDORS ARE PERFORMING IN TERMS OF REVENUE GENERATION AND CUSTOMER BASE COMPARED TO OTHERS. KNOWING MARKET SHARE OFFERS AN IDEA OF THE SIZE AND COMPETITIVENESS OF THE VENDORS FOR THE BASE YEAR. IT REVEALS THE MARKET CHARACTERISTICS IN TERMS OF ACCUMULATION, FRAGMENTATION, DOMI

GLOBAL CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET RESEARCH REPORT REPORT TO 2027 - TECHNOLOGICAL ADVANCEMENTS IN CARDIAC RESYNCHRONIZATION THERAPY DEVICES PRESENTS OPPORTUNITIES - RESEARCHANDMARKETS.COM

IRVINE, CALIF.--(BUSINESS WIRE)--APPRISS RETAIL, AN INDUSTRY LEADER IN DATA SCIENCE THAT TRANSFORMS THE CONSUMER PURCHASE CYCLE, TODAY ANNOUNCED THE RESULTS OF A NEW SURVEY IN PARTNERSHIP WITH INCISIV. THE 2022 STATE OF THE INDUSTRY: RETURNS AS AN ENGAGEMENT STRATEGY REPORT FOUND THAT RETAILERS WHO TREAT RETURNS WITH A ONE-SIZE-FITS-ALL APPROACH WILL MISS OUT ON IMPORTANT ENGAGEMENT OPPORTUNITIES. THE SURVEY ASKED OVER 130 RETAILERS ABOUT THEIR OUTLOOKS REGARDING RETURNS AS A CUSTOMER ENGAGEMENT OPPORTUNITY, AS WELL AS THEIR CHALLENGES, CAPABILITIES AND FUTURE PLANS FOR STRATEGICALLY IMPROVING OVERALL RETURNS PERFORMANCE. ONLINE ORDER RETURN RATES ARE THREE TO FOUR TIMES HIGHER THAN STORE-BOUGHT PURCHASES THE GROWTH OF ECOMMERCE HAS INCREASED RETURN RATES SIGNIFICANTLY, BUT MANY RETAILERS HAVE NOT ADJUSTED THEIR RETURNS STRATEGY ACCORDINGLY. A LARGE MAJORITY (69%) OF RETAILERS ARE STILL TREATING RETURNS AS A COST OF DOING BUSINESS, DESPITE RECOGNIZING THE BENEFITS OF OPTIMIZING RETURNS MANAGEMENT. IN FACT, RESULTS FROM THE SURVEY SHOWED THAT: RETURN RATES ARE GROWING FASTER THAN REVENUE GROWTH RATES FOR 91% OF RETAILERS. MOST RETAILERS (69%) LACK A GOOD UNDERSTANDING OF THE ROOT CAUSE OF THEIR RETURNS. ONLY 29% OF RETAILERS HAVE AN END-TO-END STRATEGIC RETURNS MANAGEMENT PROGRAM IN PLACE. RETAILERS SEE THE VALUE IN OPTIMIZING RETURNS BUT LACK FOLLOW-THROUGH OPTIMIZING RETURNS IS A REQUIREMENT FOR LONG-TERM PROFITABILITY AND CUSTOMER LOYALTY. IN FACT, 42% OF SHOPPERS WILL STOP SUPPORTING A RETAILER AFTER MULTIPLE RETAILER-INDUCED RETURNS. RETAILERS UNDERSTAND THE IMPORTANCE OF IMPROVING RETURNS PERFORMANCE BUT THERE IS A MAJOR GAP BETWEEN INTENT AND EXECUTION. THE REPORT FOUND THAT: REDUCING RETURN RATES IS A TOP PRIORITY FOR 83% OF RETAILERS BUT ONLY 21% BELIEVE THEIR CURRENT PROCESSES ARE EFFECTIVE AT DOING SO. SIMILARLY, 77% OF RETAILERS ARE INTERESTED IN OPTIMIZING THE COST OF REVERSE LOGISTICS BUT ONLY 29% ARE CURRENTLY ACHIEVING TOWARDS THIS GOAL. DESPITE 64% O

ONLY 18% OF RETAILERS OPTIMIZE RETURN RATES FOR MAJOR PRODUCT CATEGORIES

DUBLIN--(BUSINESS WIRE)--THE "GLOBAL CARDIAC RESYNCHRONIZATION THERAPY (CRT) DEVICES MARKET - ANALYSIS BY PRODUCT (CRT-D, CRT-P), END-USER BY REGION, BY COUNTRY (2022 EDITION): MARKET INSIGHTS AND FORECAST WITH IMPACT OF COVID-19 (2022-2027)" REPORT HAS BEEN ADDED TO RESEARCHANDMARKETS.COM'S OFFERING. THE GLOBAL CARDIAC RESYNCHRONIZATION THERAPY (CRT) DEVICES MARKET WAS VALUED AT USD 7.14 BILLION IN THE YEAR 2021 WITH AMERICAS REGION LEADING THE REGIONAL MARKET SHARE. COMPANY PROFILES MEDTRONIC PLC BOSTON SCIENTIFIC ABBOTT LABORATORIES BIOTRONIK MICROPORT SCIENTIFIC CORPORATION LIVANOVA PLC MEDICO S.P.A EBR SYSTEMS ONE OF THE MAIN FACTORS DRIVING THIS MARKET IS THE RISING PREVALENCE OF CARDIOVASCULAR DISEASES (CVDS) THAT LEAD TO HEART FAILURE (HF). EACH YEAR, APPROXIMATELY 3.5 MILLION PEOPLE SUFFER FROM HF WORLDWIDE FOSTERING THE DEMAND FOR CARDIAC RESYNCHRONIZATION THERAPY DEVICES. ADDITIONALLY, FACTORS SUCH AS TECHNOLOGICAL ADVANCEMENTS IN DEVICES, EXPANDING CRT PRODUCT DEVELOPMENTS, KEY COMPANY INITIATIVES & INVESTMENTS, SEDENTARY LIFESTYLES AND AGEING DEMOGRAPHICS AROUND THE WORLD ARE ANTICIPATED TO IMPEL THE MARKET GROWTH IN THE FORECAST PERIOD. THE ASIA PACIFIC CRT DEVICES MARKET IS PREDICTED TO BE THE HOTSPOT AND THE MOST LUCRATIVE REGION FOR THE MARKET PARTICIPANTS WORLDWIDE. SOME OF THE MAJOR FACTORS PROPELLING THE GROWTH OF THE CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET IN THE ASIA PACIFIC REGION INCLUDE A FAVOURABLE REIMBURSEMENT SCENARIO IN JAPAN, AN AGEING POPULATION IN CHINA, AN INCREASE IN CVD INCIDENCE, AN IMPROVED HEALTHCARE INFRASTRUCTURE, AN EXPANDING MIDDLE-CLASS POPULATION, AND RISING DISPOSABLE INCOME LEVELS IN INDIA. THE CARDIAC RESYNCHRONIZATION THERAPY (CRT) DEVICES MARKET EXPERIENCED A PERIOD OF A TEMPORARY SETBACK IN THE YEAR 2020 AS LOCKDOWN RESTRICTIONS WERE ENFORCED AS A NECESSARY STEP TO CURB THE SPREAD OF COVID-19 VIRUS. HOWEVER, AFTER THE INITIAL SHOCK AND CONFUSION ABOUT COVID-19, COMPANIES AND GOVERNMENTS BEGAN TAKING CORRECT

GLOBAL CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET REPORT TO 2027 - FEATURING MEDTRONIC, BOSTON SCIENTIFIC AND BIOTRONIK AMONG OTHERS - RESEARCHANDMARKETS.COM

SAN FRANCISCO--(BUSINESS WIRE)--AIZON ANNOUNCED TODAY THE LAUNCH OF ITS NEW GXP-COMPLIANT DATA PROCESSING PRODUCT, AIZON DIGITIZE. DIGITIZE PROVIDES LIFE SCIENCES MANUFACTURERS WITH A SOLUTION TO HELP SPEARHEAD THEIR DIGITAL TRANSFORMATION, RAMPING UP PRODUCTIVITY AND AVOIDING TIME-CONSUMING DATA INPUTS PRONE TO ERRORS. AIZON DIGITIZE AUTOMATICALLY UPLOADS PAPER RECORDS AND COMMONLY USED FILE FORMATS TO BEGIN THE CREATION OF AN AUDIT TRAIL AND IT IMMEDIATELY ENABLES TRACKING OF CHANGES TO THE DATA, AND INTEGRATES WITH EBR, LIMS, QMS AND MANUFACTURING EXECUTION SYSTEMS (MES), TO DELIVER POWERFUL INSIGHTS. THIS PREVIOUSLY INACCESSIBLE DATA IS NOW LEVERAGEABLE TO MAKE TIMELY DECISIONS TO BOTH INCREASE PRODUCTIVITY AND DECREASE COSTS. DIGITIZE IS THE FIRST STEP TOWARDS REALIZING THE FULL POTENTIAL OF APPLYING PHARMA 4.0 TECHNOLOGIES TO SOLVE THE MOST COMMON TO THE MOST COMPLEX MANUFACTURING PROBLEMS. THE LIFE SCIENCES INDUSTRY IS ACCELERATING THE ADOPTION OF PHARMA 4.0 TECHNOLOGIES TO ADDRESS THE NEED TO INCREASE QUALITY AND CAPACITY, REQUIRING A MASSIVE TRANSFORMATION IN THE WAY DRUGS AND VACCINES ARE MANUFACTURED. ADDITIONALLY, INTENSIFYING COMPETITION AND ENHANCED REGULATORY GUIDANCE ARE SHIFTING INVESTMENT PRIORITIES FOR PHARMACEUTICAL COMPANIES TO FOCUS ON OPTIMIZING EXISTING MANUFACTURING PROCESSES. WITH APPROXIMATELY 30% OF AVAILABLE DATA BEING LEVERAGED TO IMPROVE THESE PROCESSES, MANUFACTURERS HAVE A TREMENDOUS OPPORTUNITY TO CREATE A HOLISTIC VIEW OF THEIR OPERATIONS AND SHIFT TO A PREDICTIVE OPERATION, PROVIDING MUCH GREATER INSIGHT TO EMPOWER THE USERS TO MAKE MORE TIMELY AND ACCURATE DECISIONS. MANY PHARMACEUTICAL MANUFACTURERS STILL RELY ON MANUAL ENTRIES AND PROCESSES TO PERFORM CRITICAL TASKS. THIS VERY COMMON APPROACH EXPONENTIALLY INCREASES THE RISK OF INTRODUCING ERRORS AND HINDERING THEIR ABILITY TO OPTIMIZE THE ENTIRE DEVELOPMENT AND MANUFACTURING PROCESS, SAID JOHN VITALIE, CEO, AIZON. AIZON DIGITIZE HELPS USERS AVOID UNNECESSARY MANUAL ENTRY AND T

AIZON LAUNCHES GXP-COMPLIANT DATA PROCESSING SOLUTION TO ACCELERATE DIGITAL TRANSFORMATION FOR LIFE SCIENCES MANUFACTURING

DUBLIN--(BUSINESS WIRE)--THE "CARDIAC RESYNCHRONISATION THERAPY (CARDIOVASCULAR) - GLOBAL MARKET ANALYSIS AND FORECAST MODEL" REPORT HAS BEEN ADDED TO RESEARCHANDMARKETS.COM'S OFFERING. THE REPORT WAS BUILT TO VISUALIZE QUANTITATIVE MARKET TRENDS WITHIN CARDIOVASCULAR DEVICES THERAPEUTIC AREA. THE MODEL DISCUSSES IN DETAIL THE IMPACT OF COVID-19 ON CARDIAC RESYNCHRONISATION THERAPY MARKET FOR THE YEAR 2020 AND BEYOND. CARDIAC RESYNCHRONISATION THERAPY HAS BECOME A WIDELY ACCEPTED OPTION WHICH RESTORES A BETTER PHYSIOLOGICAL PATTERN OF CONTRACTIONS TO THE DESYNCHRONIZED HEARTS. SECONDARY SOURCES INDICATE THAT CRT HAS PROVEN TO REDUCE THE MORBIDITY AND MORTALITY IN PATIENTS AT A LARGE SCALE. VENTRICULAR DYSSYNCHRONY, INTERVENTRICULAR CONDUCTION DELAY, VENTRICULAR TACHYCARDIA AND VENTRICULAR FIBRILLATION HAVE BECOME THE BASIS OF CARDIAC RESYNCHRONISATION THERAPY AS IT LEADS TO SIGNIFICANT IMPROVEMENTS IN SYMPTOMS AND SURVIVAL OF PATIENTS. EACH OF THE COVERED 39 COUNTRY'S COLOR-CODED AND FULLY-SOURCED MARKET MODELS ARE EQUIPPED WITH EPIDEMIOLOGY BASED INDICATIONS WITH PROCEDURE VOLUMES. TO INCREASE THE DATA TRANSPARENCY, THE INTERACTIVE EXCEL DELIVERABLE COVERS INSTALLED BASE, NEW SALES VOLUMES, PRODUCT USAGE, AVERAGE SELLING PRICES, MARKET SIZE AND COMPANY SHARE/RANK ANALYSIS (WHEREVER AVAILABLE). MOREOVER, ANALYST COMMENTS WITH QUALITATIVE INSIGHT OFFER CONTEXT FOR QUANTITATIVE DATA. KEY INCLUSIONS OF THE MARKET MODEL ARE: CURRENTLY MARKETED CARDIAC RESYNCHRONISATION THERAPY AND EVOLVING COMPETITIVE LANDSCAPE: INSIGHTFUL REVIEW OF THE KEY INDUSTRY TRENDS. ANNUALIZED TOTAL CARDIAC RESYNCHRONISATION THERAPY MARKET REVENUE BY SEGMENT AND MARKET OUTLOOKS FROM 2015-2030. GRANULAR DATA ON TOTAL PROCEDURES, UNITS, AVERAGE SELLING PRICES AND MARKET VALUES BY SEGMENT. GLOBAL, REGIONAL AND COUNTRY LEVEL MARKET SPECIFIC INSIGHTS: QUALITATIVE MARKET SPECIFIC INFORMATION IS AVAILABLE WITH GLOBAL TRENDS FURTHER BROKEN DOWN INTO REGIONAL TRENDS. IN ADDITION THE ANALYST PROVIDES UNIQ

CARDIAC RESYNCHRONISATION THERAPY MARKET ANALYSIS AND FORECAST MODEL 2022 - RESEARCHANDMARKETS.COM

DUBLIN--(BUSINESS WIRE)--THE "CARDIAC RHYTHM MANAGEMENT DEVICES - MEDICAL DEVICES PIPELINE PRODUCT LANDSCAPE, 2021" REPORT HAS BEEN ADDED TO RESEARCHANDMARKETS.COM'S OFFERING. THIS REPORT PROVIDES COMPREHENSIVE INFORMATION ABOUT THE CARDIAC RHYTHM MANAGEMENT DEVICES PIPELINE PRODUCTS WITH COMPARATIVE ANALYSIS OF THE PRODUCTS AT VARIOUS STAGES OF DEVELOPMENT AND INFORMATION ABOUT THE CLINICAL TRIALS WHICH ARE IN PROGRESS. CARDIAC RHYTHM MANAGEMENT (CRM) DEVICES ARE THOSE DEVICES WHICH ARE USED TO RESTORE THE NATURAL SYNCHRONIZED PUMPING RHYTHM OF THE HEART. THESE INCLUDE PACEMAKERS, CARDIAC RESYNCHRONISATION THERAPY (CRT), IMPLANTABLE LOOP RECORDERS AND IMPLANTABLE CARDIOVERTER DEFIBRILLATORS (ICD). SCOPE EXTENSIVE COVERAGE OF THE CARDIAC RHYTHM MANAGEMENT DEVICES UNDER DEVELOPMENT THE REPORT REVIEWS DETAILS OF MAJOR PIPELINE PRODUCTS WHICH INCLUDES, PRODUCT DESCRIPTION, LICENSING AND COLLABORATION DETAILS AND OTHER DEVELOPMENTAL ACTIVITIES THE REPORT REVIEWS THE MAJOR PLAYERS INVOLVED IN THE DEVELOPMENT OF CARDIAC RHYTHM MANAGEMENT DEVICES AND LIST ALL THEIR PIPELINE PROJECTS THE COVERAGE OF PIPELINE PRODUCTS BASED ON VARIOUS STAGES OF DEVELOPMENT RANGING FROM EARLY DEVELOPMENT TO APPROVED / ISSUED STAGE THE REPORT PROVIDES KEY CLINICAL TRIAL DATA OF ONGOING TRIALS SPECIFIC TO PIPELINE PRODUCTS RECENT DEVELOPMENTS IN THE SEGMENT / INDUSTRY REASONS TO BUY THE REPORT ENABLES YOU TO: FORMULATE SIGNIFICANT COMPETITOR INFORMATION, ANALYSIS, AND INSIGHTS TO IMPROVE R&D STRATEGIES IDENTIFY EMERGING PLAYERS WITH POTENTIALLY STRONG PRODUCT PORTFOLIO AND CREATE EFFECTIVE COUNTER STRATEGIES TO GAIN COMPETITIVE ADVANTAGE IDENTIFY AND UNDERSTAND IMPORTANT AND DIVERSE TYPES OF CARDIAC RHYTHM MANAGEMENT DEVICES UNDER DEVELOPMENT DEVELOP MARKET-ENTRY AND MARKET EXPANSION STRATEGIES PLAN MERGERS AND ACQUISITIONS EFFECTIVELY BY IDENTIFYING MAJOR PLAYERS WITH THE MOST PROMISING PIPELINE IN-DEPTH ANALYSIS OF THE PRODUCT'S CURRENT STAGE OF DEVELOPMENT, TERRITORY AND ESTIMATED LAUNCH DAT

2021 CARDIAC RHYTHM MANAGEMENT DEVICES MEDICAL DEVICES PIPELINE PRODUCT LANDSCAPE REPORT - RESEARCHANDMARKETS.COM

SUNNYVALE, CALIF.--(BUSINESS WIRE)--AUSTRALIAN INVESTORS STRONG APPETITE FOR HEALTHCARE STOCK CONTINUES WITH THE AU$110M LISTING OF CARDIOVASCULAR MEDICAL DEVICE COMPANY, EBR SYSTEMS, AT 11AM AEDT NOVEMBER 24 ON THE AUSTRALIAN SECURITIES EXCHANGE (ASX). SILICON VALLEY-BASED EBR SYSTEMS IS PIONEERING LEADLESS PACEMAKING TECHNOLOGY. THE COMPANYS WISE CRT SYSTEM IS THE WORLDS FIRST AND ONLY WIRELESS, INSIDE-THE-LEFT-VENTRICLE-OF-THE-HEART PACING SYSTEM FOR HEART FAILURE, AND IS APPROVED FOR USE IN EUROPE. CAPITAL RAISED FROM NEXT WEEKS LISTING WILL PROVIDE EBR SYSTEMS WITH THE EQUITY TO COMPLETE ITS PIVOTAL STUDY, TARGETING U.S. FOOD & DRUG ADMINISTRATION (FDA) SUBMISSION FOR APPROVAL IN 2023, FOLLOWED BY RAPID COMMERCIAL LAUNCH IN THE U.S., AUSTRALIA AND OTHER KEY MARKETS. MANY PATIENTS WITH HEART FAILURE REQUIRE CARDIAC RESYNCHRONIZATION THERAPY (CRT), WHICH USES LEAD-BASED CARDIAC PACING DEVICES TO COORDINATE THE BEATING OF THE LEFT AND RIGHT SIDES OF THE HEART. WISE PROVIDES A TREATMENT OPTION FOR PATIENTS UNABLE TO RECEIVE CRT FROM A TRADITIONAL LEAD-BASED SYSTEM OR THOSE AT HIGH RISK FROM AN UPGRADE PROCEDURE. WITHOUT EFFECTIVE CRT, THESE PATIENTS SUFFER POOR CLINICAL PROGNOSIS, POOR QUALITY OF LIFE AND REDUCED LIFE EXPECTANCY. ITS BEEN WONDERFUL TO SEE SUCH STRONG INVESTOR SUPPORT FOR EBRS INITIAL PUBLIC OFFERING, SAID JOHN MCCUTCHEON, PRESIDENT AND CEO OF EBR SYSTEMS. WITH AUSTRALIAS LONG TRADITION AS A GLOBAL INNOVATOR IN CARDIOLOGY TECHNOLOGY, IT IS FITTING THAT AUSTRALIAN INVESTORS WILL PROVIDE THE FINANCIAL BACKING AS WE PIONEER LEADLESS LV PACING SO THAT IT CAN HELP TO IMPROVE THE LIVES OF HEART FAILURE PATIENTS IN AUSTRALIA AND AROUND THE WORLD. IN OCTOBER, EBR SUCCESSFULLY COMPLETED AN AU$110M UNDERWRITTEN CAPITAL RAISE, WHICH WAS STRONGLY SUPPORTED BY NEW AND EXISTING INSTITUTIONAL SHAREHOLDERS. EXISTING AUSTRALIAN INSTITUTIONAL INVESTORS INCLUDING INCLUDE BRANDON CAPITAL, M.H. CARNEGIE & CO, HOSTPLUS, TELSTRASUPER AND HESTA CONTRIBUTED MORE AU$30M OF T

EBR SYSTEMS RAISES AU$110M IN INITIAL PUBLIC OFFERING ON THE AUSTRALIAN SECURITIES EXCHANGE (ASX)

SUNNYVALE, CALIF.--(BUSINESS WIRE)--EBR SYSTEMS, INC., DEVELOPER OF THE WORLDS ONLY WIRELESS CARDIAC PACING SYSTEM FOR HEART FAILURE, TODAY ANNOUNCED THE APPOINTMENT OF DR BRONWYN EVANS, DR DAVID STEINHAUS AND MS KAREN DREXLER TO THE BOARD AS INDEPENDENT NON-EXECUTIVE DIRECTORS. DR EVANS IS AN EXPERIENCED LEADER AND CEO WITH A BROAD TECHNICAL BACKGROUND ACROSS MULTIPLE INDUSTRY SECTORS. SHE IS CURRENTLY THE CEO OF ENGINEERS AUSTRALIA, THE CHAIR OF BUILDING 4.0 CRC AND A DIRECTOR AT GME PTY LTD. SHE HAS AN EXTENSIVE BACKGROUND IN THE HEALTHCARE INDUSTRY HAVING PREVIOUSLY SERVED AS THE CEO OF STANDARDS AUSTRALIA, SENIOR VICE PRESIDENT OF QUALITY, CLINICAL & REGULATORY AT COCHLEAR LIMITED (ASX:COH) AND HELD MULTIPLE OTHER EXECUTIVE ROLES. SHE WAS NAMED AS ONE OF AUSTRALIAS TOP 100 INFLUENTIAL WOMEN IN 2016 AND HOLDS A BACHELORS DEGREE AND A PHD IN ELECTRICAL ENGINEERING FROM THE UNIVERSITY OF WOLLONGONG. DR STEINHAUS WAS FORMERLY VICE PRESIDENT AND GENERAL MANAGER OF THE HEART FAILURE BUSINESS FOR THE CARDIAC RHYTHM AND HEART FAILURE DIVISION AT MEDTRONIC PLC (NYSE:MDT). DR STEINHAUS HAS EXTENSIVE CLINICAL AND BUSINESS EXPERIENCE IN CARDIAC RHYTHM MANAGEMENT, INCLUDING PERFORMING NUMEROUS CLINICAL STUDIES IN IMPLANTABLE CARDIAC DEVICES AND LEADS. HE IS CURRENTLY THE EXECUTIVE CHAIRMAN OF THE BOARD AT ENOPACE BIOMEDICAL LTD., A COMPANY WHICH PRODUCES THERAPEUTIC NEUROMODULATION DEVICES FOR THE TREATMENT OF HEART FAILURE AND SERVES AS A CONSULTANT AND BOARD MEMBER FOR MULTIPLE ESTABLISHED AND EARLY-STAGE MEDICAL DEVICE COMPANIES. DR STEINHAUS IS A MAGNA CUM LAUDE GRADUATE OF HARVARD COLLEGE AND RECEIVED HIS MEDICAL DOCTORATE FROM HARVARD MEDICAL SCHOOL AS PART OF THE HARVARD-M.I.T. PROGRAM IN HEALTH SCIENCES AND TECHNOLOGY, WITH ALPHA OMEGA ALPHA (AOA) HONOURS. MS DREXLER BRINGS AN ARRAY OF OPERATIONAL AND ENTREPRENEURIAL EXPERIENCE TO EBR SYSTEMS BOARD. SHE IS CURRENTLY A DIRECTOR AT RESMED INC. (NYSE, ASX: RMD), WHERE SHE SERVES ON THE COMPENSATION COMMITTEE AND ON THE

Centrais Eltricas Brasileiras S.A. - Eletrobrs

EBR

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Centrais Eltricas Brasileiras S.A. - Eletrobrs

EBR.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

EBR